US Cephalexin prices softened during the first half of June as the strong restocking activity that supported the market in May began to ease. Buyers became less aggressive in securing material after earlier inventory replenishment, while lower import-related costs and improved logistics conditions contributed to a more balanced market environment. Stable raw material costs provided little support for further price increases, allowing downward pressure to emerge. The strength seen in May was largely driven by robust demand from hospitals, pharmacies, and pharmaceutical manufacturers that replenished inventories following seasonal drawdowns. Additional support came from wholesale distributors seeking to secure supply amid concerns over higher logistics expenses and tighter availability. At the same time, disciplined production from key exporting regions and constrained spot allocations reduced immediate supply and supported market firmness. Looking ahead, analysts expect mild weakness to continue through the second half of June as immediate restocking needs remain limited and overseas offers stay competitive. Nevertheless, stable pharmaceutical demand and seasonal healthcare needs are expected to underpin market stability in the coming months.
